Pennsylvania Access Score: 61.3/100
Composite of methadone OTP density, buprenorphine provider density, mental health shortage need-met %, Medicaid coverage breadth, 1115 SUD waiver status, and legal protections. How we score.
Pennsylvania has 65 currently SAMHSA-certified opioid treatment programs across 50 cities. Methadone is dispensed daily on-site at OTPs, which is the regulatory boundary that defines this list.
Composite analysis
Pennsylvania ranks among the states with the least treatment access pressure on this index. Provider density is comparatively strong and acute demand signals are softer.
TAPI is a CCIWA composite. Each input is z-scored across 50 states plus DC and Puerto Rico, then combined as a weighted sum (HPSA 30%, frequent mental distress 25%, unemployment 15%, treatment density 30%, sign-flipped). The result is rescaled 0 to 100 by percentile rank. Read the full methodology.
Composite of methadone OTP density, buprenorphine provider density, mental health shortage need-met %, Medicaid coverage breadth, 1115 SUD waiver status, and legal protections. How we score.
| Component | Detail | Points |
|---|---|---|
| OTP density | 0.501 OTPs per 100K residents | 15 / 30 |
| Buprenorphine density | 6.47 providers per 100K | 5.2 / 20 |
| Mental health HPSA need met | 33.39% | 11.1 / 20 |
| Medicaid breadth | 5 of 5 service categories covered | 15 / 15 |
| 1115 SUD waiver | Active | 10 / 10 |
| Legal protections | Good Samaritan: Yes · Naloxone access: Yes | 5 / 5 |
| Service | Covered | Notes |
|---|---|---|
| Methadone | Yes | Prior auth required |
| Buprenorphine | Yes | |
| Naltrexone (Vivitrol) | Yes | |
| Outpatient SUD | Yes | |
| Residential SUD | Yes |
1115 SUD waiver: Active. IMD exclusion waived. Expires 2022-09-30 (current/prior period); renewal requested through 2027-09-30.